SCILEX HOLDING COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.090 USD | -5.22% |
|
+6.86% | -46.57% |
| 09-12 | Scilex Gets Drug Distributor Accreditation from National Association of Boards of Pharmacy | MT |
| 09-03 | Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
Pharmaceutical Products | |||||
Development of Non-Opioid Products | 21.03M | 23.56M | 31.32M | 38.03M | 46.74M |
Total Assets | - | 81.5M | 77.93M | 86.53M | 101M |
Interest Expense | -16.89M | -13.12M | -11.76M | -9.6M | -1.07M |
Income Tax Expense | 2K | -53K | 5K | 4K | 13K |
CAPEX | -584K | -25K | - | -2.07M | -30K |
EBT | -179M | -47.57M | -88.42M | -23.36M | -114M |
D&A | 3.75M | 3.78M | 3.78M | 3.96M | 4.15M |
Operating Income | -139M | -35.26M | -35.84M | -50.63M | -105M |
Net Income | -179M | -47.52M | -88.42M | -23.36M | -114M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
United States | 21.03M | 23.56M | 31.32M | 38.03M | 46.74M |
Total Assets | - | 81.5M | 77.93M | 86.53M | 101M |
Interest Expense | -16.89M | -13.12M | -11.76M | -9.6M | -1.07M |
Income Tax Expense | 2K | -53K | 5K | 4K | 13K |
D&A | 3.75M | 3.78M | 3.78M | 3.96M | 4.15M |
CAPEX | -584K | -25K | - | -2.07M | -30K |
Net Income | -179M | -47.52M | -88.42M | -23.36M | -114M |
EBT | -179M | -47.57M | -88.42M | -23.36M | -114M |
Operating Income | -139M | -35.26M | -35.84M | -50.63M | -105M |
- Stock Market
- Equities
- SCLX Stock
- Financials Scilex Holding Company
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition